Liquid-chromatographic determination of erlotinib (OSI-774), an epidermal growth factor receptor tyrosine kinase inhibitor
作者： Erin R. Lepper , Sandra M. Swain , Antoinette R. Tan , William D. Figg , Alex Sparreboom
DOI: 10.1016/J.JCHROMB.2003.08.015
关键词: Quantitative analysis (chemistry) 、 Erlotinib Hydrochloride 、 Spectrophotometry 、 Chromatography 、 Acetonitrile 、 Hydrochloride 、 High-performance liquid chromatography 、 Erlotinib 、 Chemistry 、 Extraction (chemistry)
摘要: A high-performance liquid-chromatographic (HPLC) assay with UV detection has been developed for the quantitative determination of erlotinib (OSI-774) in human plasma. Quantitative extraction was achieved by a single-solvent involving mixture acetonitrile and n-butyl chloride (1:4, v/v). Erlotinib internal standard hydrochloride salt (OSI-597) were separated on column packed Nova-Pak C18 material mobile phase composed water, pH 2.0 (60:40, The effluent monitored dual at wavelengths 348 nm (erlotinib) 383 (OSI-597). calibration graph linear range 100-4500 ng/ml, values accuracy precision ranging from 87.9 to 96.2% 2.13 5.10%, respectively, three different sets quality control samples. method successfully applied study pharmacokinetics cancer patient recommended daily dose 150 mg.
elsevier.com
sci-hub.se 参考文章(12)
Norman P, OSI-774 OSI Pharmaceuticals. Current opinion in investigational drugs. ,vol. 2, pp. 298- 304 ,(2001)
Analytical methods validation: bioavailability, bioequivalence and pharmacokinetic studies. Conference report. European Journal of Drug Metabolism and Pharmacokinetics. ,vol. 16, pp. 249- ,(1991) , 10.1007/BF03189968
J.R Woodburn, The epidermal growth factor receptor and its inhibition in cancer therapy. Pharmacology & Therapeutics. ,vol. 82, pp. 241- 250 ,(1999) , 10.1016/S0163-7258(98)00045-X
C Hartmann, J Smeyers-Verbeke, D.L Massart, R.D McDowall, Validation of bioanalytical chromatographic methods. Journal of Pharmaceutical and Biomedical Analysis. ,vol. 17, pp. 193- 218 ,(1998) , 10.1016/S0731-7085(97)00198-2
W.J Loos, J Verweij, K Nooter, G Stoter, A Sparreboom, Sensitive determination of docetaxel in human plasma by liquid-liquid extraction and reversed-phase high-performance liquid chromatography Journal of Chromatography B: Biomedical Sciences and Applications. ,vol. 693, pp. 437- 441 ,(1997) , 10.1016/S0378-4347(97)00089-3
Joan H Schiller, New directions for ZD1839 in the treatment of solid tumors Seminars in Oncology. ,vol. 30, pp. 49- 55 ,(2003) , 10.1053/SONC.2003.50032
David S. Salomon, Ralf Brandt, Fortunato Ciardiello, Nicola Normanno, Epidermal growth factor-related peptides and their receptors in human malignancies Critical Reviews in Oncology Hematology. ,vol. 19, pp. 183- 232 ,(1995) , 10.1016/1040-8428(94)00144-I
V GRUNWALD, M HIDALGO, The epidermal growth factor receptor: a new target for anticancer therapy. Current Problems in Cancer. ,vol. 26, pp. 114- 164 ,(2002) , 10.1067/MCN.2002.125874
Elsa G. Barbacci, Leslie R. Pustilnik, John L. Doty, Deborah A. Baker, Kenneth K. Iwata, Lee D. Arnold, Michael J. Morin, James D. Moyer, Douglas M. Savage, Konstantinos E. Tsaparikos, Teresa A. Smolarek, Donald E. Sloan, Madhur P. Vaidya, Vincent A. Pollack, John A. Davis, Inhibition of Epidermal Growth Factor Receptor-Associated Tyrosine Phosphorylation in Human Carcinomas with CP-358,774: Dynamics of Receptor Inhibition In Situ and Antitumor Effects in Athymic Mice Journal of Pharmacology and Experimental Therapeutics. ,vol. 291, pp. 739- 748 ,(1999)
Manuel Hidalgo, Lillian L. Siu, John Nemunaitis, Jinee Rizzo, Lisa A. Hammond, Chris Takimoto, S. Gail Eckhardt, Anthony Tolcher, Carolyn D. Britten, Louis Denis, Karen Ferrante, Daniel D. Von Hoff, Sandra Silberman, Eric K. Rowinsky, Phase I and Pharmacologic Study of OSI-774, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Advanced Solid Malignancies Journal of Clinical Oncology. ,vol. 19, pp. 3267- 3279 ,(2001) , 10.1200/JCO.2001.19.13.3267